Floatz logo

METHOTREXATE

Bipolar Disorder

Cedars-Sinai Medical CenterSmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

50 Active assets in the Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
LAMOTRIGINE
Johns Hopkins University
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
Paroxetine
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Phase 4BBB
CITALOPRAM
University of Texas Southwestern Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →